Introduction {#Sec1}
============

Breast cancer has by far the highest incidence of all cancer types among women around the world^[@CR1],[@CR2]^. Contrary to the recent drop in the breast cancer incidence in Western countries, the incidence in Korea has been gradually rising for more than a decade^[@CR3],[@CR4]^. The peak incidence of breast cancer in Korea is among women 45--49 years of age, whereas that in the USA and Canada is among women 75--79 years of age^[@CR5],[@CR6]^. Although estrogen exposure, unfavorable lifestyles, and genetic factors are known to be major risk factors for breast cancer, the unique epidemiological features of breast cancer among Korean women are not properly understood. Recently, insulin resistance and metabolic syndrome were shown to be associated with an increased risk of breast cancer^[@CR7]--[@CR9]^. However, among Korea women, those relationships are limited to only one subtype of breast cancer in postmenopausal women^[@CR10]^.

An increasing body of evidence suggests that chronic low-grade inflammation could be linked to the pathogenesis of some cancers^[@CR11]--[@CR13]^. White blood cell (WBC) count, an inflammatory biomarker, has become a useful predictor of certain diseases as well as a marker of infection^[@CR14]--[@CR17]^. An elevated WBC count, even within the normal range, has been associated with cancer incidence and mortality and with atherosclerotic cardiovascular diseases^[@CR18]--[@CR20]^. The role of WBC count as a surrogate for inflammation has not been examined in the context of well-known effect modifiers for breast cancer development.

Previous epidemiological studies have demonstrated that obesity, as indicated by body mass index (BMI), can influence the breast cancer risk, which can be altered differently according to menopausal status^[@CR21]--[@CR23]^. Several studies have attempted to identify the association between WBC counts and breast cancer risk, but no consistent evidence has been found, and those studies were not conducted without stratification by menopausal status and BMI^[@CR24],[@CR25]^. Furthermore, hormone receptor positive- and negative- breast tumors are heterogeneous with respect to risk factors and etiology^[@CR26],[@CR27]^. In this regard, we would like to shed light on the interaction between inflammation, as indicated by WBC count, and breast cancer burden according to estrogen receptor (ER) and progesterone receptor (PR) status in the context of body mass index and menopausal status. We conducted a case-control study to investigate whether WBC count is related to breast cancer burden according to ER/PR status in the context of body mass index and menopausal status.

Materials and Methods {#Sec2}
=====================

Study population {#Sec3}
----------------

We selected patients with breast cancer from the breast cancer registry of the Department of Surgery, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea, which includes anthropometric measures, laboratory data, personal medical history, and clinicopathological features of breast cancers. The Institutional Review Board of Yonsei University College of Medicine approved the study. We included in the study 4402 female Korean patients who were diagnosed with *in situ* or invasive carcinoma of the breast between November 2005 and December 2012 and subsequently underwent surgery for breast cancer. Throughout this period, baseline characteristics of breast cancer patients were similar and sequentially registered enough to secure proper stratification by BMI, menopausal status, and hormone receptor status. We excluded patients for whom there was no available information about menopause or BMI, those with Stage IV breast cancer, and those less than 20 years of age at the time of diagnosis (Fig. [1](#Fig1){ref-type="fig"}).Figure 1Selection of patients and controls for the study.

We selected 4402 propensity score-matched controls from the 2010--2012 Korean National Health and Nutrition Examination Survey (KNHANES), which was, as a fifth period survey, sampled without duplication of participants and performed on well-refined setting, while the earlier KNHANES were sampled again at every period due to the possibility of collective and relative duplication of missing data. We used households as the sampling units and selected individuals using a stratified, multistage, probability-sampling design according to geographic area, sex, and age. We excluded males, individuals with unknown menopause status or BMI, and individuals with a history of cancer. We assigned each eligible individual a sampling weight indicating the probability of being sampled. Therefore, we consider our results to appropriately represent the entire Korean population.

Data collection {#Sec4}
---------------

We adopted the same variables for analysis from the Severance Hospital registry and the KNHANES. Body weight and height were measured to the nearest 0.1 kg and 0.1 cm, respectively, with the participants wearing light indoor clothing without shoes. BMI was calculated as the ratio of weight (kg) to squared height (m^2^). After a 12 h overnight fast, blood samples were obtained through an antecubital vein from the controls. WBC counts were quantified using XE-2100D (Sysmex, Japan). Fasting plasma glucose, total cholesterol, triglyceride, HDL-cholesterol, aspartate aminotransferase (AST), and alanine aminotransferase (ALT) were measured using an automated chemistry analyzer (Hitachi 7600, Tokyo, Japan). Also, an overnight-fasting venous blood specimen was collected from all patients within one week after breast cancer diagnosis. WBC counts were quantified by an automated blood cell counter (ADVIA 120, NY, USA). Fasting plasma glucose, total cholesterol, triglyceride, HDL-cholesterol, AST, and ALT were measured using Hitachi 7600--110 Chemistry System Autoanalyzer (Hitachi, Tokyo, Japan). Previous study comparing automated blood cell counters has shown that there is no difference in reference intervals for WBC counts between two analyzers used in controls and cases, respectively^[@CR28]^. After definitive surgery for breast cancer, tumor specimens were stained for ER and PR. Specimens with more than 1% nuclear-stained cells were defined as positive for ER and/or PR according to the guidelines of the American Society of Clinical Oncology-College of American Pathologists^[@CR29]^. Menopause status, menarchial age, menopausal age, and history of breastfeeding were documented among the patients and the controls by a self-administered questionnaire. Menopause was defined as the cessation of menstruation for more than 12 months or surgical menopausal status in cases and controls.

Statistical analysis {#Sec5}
--------------------

We compared the characteristics of the patients and propensity score-matched controls using paired t-tests for continuous variables and McNemar's test for categorical variables. Propensity score was created using age, the most well-known confounding variable. We examined potential effects on WBC counts of obesity (BMI ≥ 25 kg/m²) and ER/PR status (ER^−^/PR^−^, ER^+^/PR^−^ or ER^−^/PR^+^, or ER^+^/PR^+^) according to menopausal status. This stratification was based on previous meta-analysis showing the different association between body weight and breast cancer risk among ER^−^/PR^−^, ER^+^/PR^−^ or ER^−^/PR^+^, or ER^+^/PR^+^ by menopausal status^[@CR27]^. We performed an analysis of covariance (ANCOVA) adjusted for WBC counts of controls to compare differences in WBC counts between matched patients and controls among groups in which the patients were ER^−^/PR^−^, ER^+^/PR^−^ or ER^−^/PR^+^, or ER^+^/PR^+^. Using multinomial logistic regression, we measured the strength of correlation between WBC count (×10^3^ cells/μL) and breast cancer burden according to ER/PR status stratified by BMI and menopause after adjusting for continuous variables (age, systolic blood pressure, fasting plasma glucose, total cholesterol, triglyceride, HDL-cholesterol, ALT, and age at menarche or age at menopause) and categorical variables (breastfeeding, hypertension medication, and diabetes medication), including significant variables (*p* \< 0.05) in univariate analysis with clinically important variables, while further considering multicollinearity. To test the combined effect of menopause status, BMI, and WBC, we tested their interactions with the interaction term for menopause status\*BMI\*WBC by multinomial logistic regression models for outcome. The interaction among menopause status, BMI, and WBC was tested at a significance level of 0.2. We conducted all analyses using the SAS statistical software, version 9.2 (SAS Institute Inc., Cary, NC, USA). All statistical tests were two-sided, with statistical significance determined by *p* \< 0.05.

Results {#Sec6}
=======

Table [1](#Tab1){ref-type="table"} shows the characteristics of the patients and matched controls according to menopausal status. The mean age of the premenopausal and postmenopausal women was 42.5 ± 6.1 years and 58.5 ± 7.7 years, respectively. The percentage of premenopausal women was 51.8%. Among the premenopausal women, the mean BMI of the controls (22.7 ± 3.1 kg/m^2^) was higher than that of the patients (22.5 ± 3.1 kg/m^2^; *p* \< 0.001). There was no significant difference in mean BMI between the postmenopausal controls (24.2 ± 3.3 kg/m^2^) and patients (24.2 ± 3.2 kg/m^2^). Regardless of menopausal status, the patients in each group had higher WBC counts, systolic blood pressure, diastolic blood pressure, and fasting plasma glucose than the controls (*p* \< 0.001 for each comparison). HDL cholesterol was lower in the premenopausal patients than in the matched controls, while there was no difference in HDL cholesterol between the postmenopausal patients and controls. Regardless of menopausal status, history of breastfeeding was more prevalent among the controls, whereas history of medication for hypertension was more prevalent among the patients. History of medication for diabetes was more prevalent among the postmenopausal patients than among the matched controls, however there was no difference in history of diabetes medication between the premenopausal patients and controls.Table 1Characteristics of breast cancer patients and age-matched controls according to menopausal status.Premenopausal womenPostmenopausal womenControls^a^\
(N = 2280)Patients\
(N = 2280)*p* value^b^Controls^a^\
(N = 2122)Patients\
(N = 2122)*p* value^b^Age (years)42.5 (6.1)42.5 (6.1)0.99958.5 (7.7)58.5 (7.7)0.999Body mass index (kg/m²)22.7 (3.1)22.5 (3.1)\<0.00124.2 (3.3)24.2 (3.2)0.832Systolic blood pressure (mmHg)110.6 (14.4)119.7 (13.3)\<0.001124.1 (18.0)128.4 (14.9)\<0.001Diastolic blood pressure (mmHg)72.7 (9.6)76.7 (9.9)\<0.00176.6 (10.0)79.0 (9.6)\<0.001Fasting plasma glucose (mg/dL)92.5 (18.9)97.3 (15.3)\<0.00198.6 (21.9)105.4 (25.1)\<0.001Total cholesterol (mg/dL)186.1 (32.7)179.6 (31.8)\<0.001204.0 (36.4)197.0 (35.7)\<0.001Triglyceride (mg/dL)99.2 (81.4)98.3 (67.1)0.726133.1 (80.8)127.8 (71.0)0.044HDL cholesterol (mg/dL)57.1 (12.5)55.4 (12.0)\<0.00154.2 (13.1)53.1 (12.0)0.020White blood cells (×10^3^ cells/μL)5.6 (1.6)6.0 (1.7)\<0.0015.7 (1.6)5.9 (1.6)\<0.001Aspartate aminotransferase (IU)18.5 (6.8)18.9 (15.9)0.35623.1 (10.0)22.9 (16.1)0.748Alanine aminotransferase (IU)15.7 (11.2)17.8 (24.6)0.01121.2 (17.0)22.4 (16.3)0.118Age at menarche (years)14.2 (1.7)14.3 (1.5)0.05215.8 (2.0)15.7 (1.9)0.185Age at menopause (years)49.0 (4.8)49.4 (5.4)0.002Breastfeeding (%)68.550.9\<0.00186.974.4\<0.001Hypertension medication (%)4.16.2\<0.00130.837.6\<0.001Diabetes medication (%)1.41.50.7008.613.2\<0.001Data are expressed as the mean (standard deviation) for continuous variables or as the percentage for categorical variables. ^a^Controls are propensity score-matched data. ^b^*p* values calculated using paired t-test or McNemar's test.

Premenopausal non-obese women with ER^−^/PR^−^ or ER^+^/PR^+^ breast cancer had higher WBC counts than their matched controls (*p* = 0.010 and *p* \< 0.001, respectively). Postmenopausal women with ER^+^/PR^−^ or ER^−^/PR^+^ breast cancer exhibited similar trends, but the difference between the patients and controls was not significant. In contrast to the patterns in premenopausal non-obese women, premenopausal obese women with ER^−^/PR^−^ breast cancer or ER^+^/PR^−^ or ER^−^/PR^+^ breast cancer did not have higher WBC counts than their age-matched controls, and the trend for higher WBC counts relative to those in the controls was weakened in those with ER^+^/PR^+^ breast cancer (Table [2](#Tab2){ref-type="table"}, Fig. [2a](#Fig2){ref-type="fig"}). WBC counts were significantly higher in postmenopausal women with ER^+^/PR^+^ breast cancer compared with those in matched controls, irrespective of obesity status (*p* \< 0.001 and *p* = 0.014, respectively; Table [3](#Tab3){ref-type="table"}, Fig. [2a](#Fig2){ref-type="fig"}).Table 2Characteristics of premenopausal patients with breast cancer and age-matched controls according to obesity and ER/PR status.Non-obeseControls^a^\
(N = 385)ER^−^/PR^−^\
(N = 385)*p* value^b^Controls^a^\
(N = 297)ER^+^/PR^−^ or\
ER^−^/PR^+^\
(N = 297)*P* value^b^Controls^a^\
(N = 1185)ER^+^/PR^+^\
(N = 1185)*p* value^b^Age (years)40.7 (6.7)40.7 (6.7)0.99942.2 (6.4)42.2 (6.4)0.99942.5 (5.8)42.5 (5.8)0.999Body mass index (kg/m²)21.3 (2.0)21.5 (1.9)0.12321.8 (1.9)21.7 (2.0)0.66821.7 (1.9)21.3 (1.9)\<0.001Systolic blood pressure (mmHg)106.4 (12.2)116.3 (11.8)\<0.001108.7 (12.8)117.7 (12.3)\<0.001109.5 (13.5)119.3 (13.2)\<0.001Diastolic blood pressure (mmHg)70.0 (8.4)74.1 (9.2)\<0.00171.5 (8.9)76.0 (10.4)\<0.00172.1 (9.5)76.4 (9.5)\<0.001Fasting plasma glucose (mg/dL)90.4 (10.7)96.8 (13.8)\<0.00189.2 (8.3)97.5 (16.7)\<0.00191.3 (18.3)95.8 (12.4)\<0.001Total cholesterol (mg/dL)181.4 (30.4)175.3 (31.2)0.028182.7 (33.0)179.4 (31.6)0.427186.0 (31.3)178.3 (30.8)\<0.001Triglyceride (mg/dL)86.6 (42.6)99.2 (70.1)0.01192.9 (47.9)97.3 (75.2)0.45491.1 (56.1)89.2 (54.8)0.493HDL cholesterol (mg/dL)59.8 (12.8)55.3 (12.4)\<0.00158.1 (13.0)55.3 (11.8)0.01557.7 (12.1)56.9 (12.1)0.238White blood cells (×10^3^ cell/μL)5.5 (1.4)5.8 (1.7)0.0105.6 (1.5)5.8 (1.7)0.0535.5 (1.6)6.0 (1.7)\<0.001Aspartate aminotransferase (IU)17.5 (5.3)20.4 (32.6)0.21018.0 (4.6)18.4 (5.7)0.55818.1 (6.2)18.1 (6.7)0.970Alanine aminotransferase (IU)13.8 (9.6)19.7 (50.4)0.10414.5 (6.2)17.3 (10.3)0.01714.8 (10.5)15.9 (10.2)0.073Age at menarche (years)14.1 (1.7)14.1 (1.6)0.48614.2 (1.6)14.4 (1.6)0.28314.2 (1.7)14.3 (1.5)0.057Breastfeeding (%)65.145.9\<0.00170.456.5\<0.00167.848.7\<0.001Hypertension medication (%)1.63.40.0895.15.10.9992.85.30.001Diabetes medication (%)1.00.50.4140.33.40.0060.70.90.637**ObeseControls** ^**a**^\
**(N = 92)ER** ^**−**^ **/PR** ^**−**^\
**(N = 92)*p*** **value** ^**b**^**Controls** ^**a**^\
**(N = 69)ER** ^**+**^ **/PR** ^**−**^ **or**\
**ER** ^**−**^ **/PR** ^**+**^\
**(N = 69)*P*** **value** ^**b**^**Controls** ^**a**^\
**(N = 252)ER** ^**+**^ **/PR** ^**+**^\
**(N = 252)*p*** **value** ^**b**^Age (years)42.1 (6.4)42.1 (6.4)0.99943.8 (6.4)43.8 (6.4)0.99944.9 (5.2)44.9 (5.1)0.999Body mass index (kg/m²)27.3 (1.9)27.2 (2.1)0.56828.0 (2.5)27.9 (3.1)0.87927.7 (2.5)27.5 (2.9)0.298Systolic blood pressure (mmHg)118.8 (18.3)124.5 (12.8)0.019118.8 (15.1)123.7 (13.7)0.013119.4 (16.1)126.7 (13.9)\<0.001Diastolic blood pressure (mmHg)77.4 (10.1)81.3 (10.7)0.00676.8 (9.8)78.5 (9.4)0.22778.3 (10.0)81.4 (9.5)\<0.001Fasting plasma glucose (mg/dL)102.9 (38.6)98.9 (18.9)0.517105.0 (38.4)103.6 (17.6)0.88199.4 (21.1)104.1 (23.5)0.101Total cholesterol (mg/dL)199.6 (50.5)186.1 (38.8)0.158189.0 (36.3)188.9 (42.4)0.992192.2 (33.4)189.6 (31.3)0.558Triglyceride (mg/dL)158.6 (279.0)129.8 (133.5)0.452135.5 (108.2)127.9 (64.3)0.655128.1 (67.3)117.0 (55.6)0.095HDL cholesterol (mg/dL)52.5 (12.2)50.6 (9.8)0.36949.8 (12.6)50.6 (11.6)0.71453.0 (10.8)52.2 (11.1)0.526White blood cells (×10^3^ cell/μL)6.4 (1.7)6.0 (19)0.1086.1 (2.0)6.0 (1.7)0.7316.1 (1.8)6.3 (2.0)0.201Aspartate aminotransferase (IU)19.8 (6.7)20.7 (8.5)0.54824.5 (20.6)22.4 (11.4)0.67221.0 (7.8)20.0 (13.4)0.473Alanine aminotransferase (IU)20.4 (12.2)21.4 (15.6)0.75021.5 (20.5)24.4 (12.9)0.55822.1 (15.1)22.1 (20.2)0.994Age at menarche (years)14.2 (1.7)14.0 (1.7)0.28114.0 (1.6)14.3 (1.6)0.18914.4 (1.9)14.4 (1.6)0.928Breastfeeding (%)71.157.80.06472.160.30.14472.857.6\<0.001Hypertension medication (%)10.99.80.8182.911.60.03310.713.10.386Diabetes medication (%)5.43.30.4144.51.50.3174.03.20.617Data are expressed as the mean (standard deviation) for continuous variables or the percentage for categorical variables. Non-obese and obese were defined as body mass index \<25 kg/m² and ≥25 kg/m², respectively. ^a^Controls are propensity score-matched data. ^b^*p* values calculated using paired t-test or McNemar's test.Figure 2Comparison of WBC counts between patients and matched controls (ER^−^/PR^−^, ER^+^/PR^−^ or ER^−^/PR^+^, ER^+^/PR^+^) according to menopause status and obesity status. ^\*^*P* \< 0.05, calculated by paired t-test (**a**). Differences in WBC counts between patients and matched controls according to menopause status and obesity status. ^\*^Difference between ER^−^/PR^−^ vs. ER^+^/PR^−^ or ER^−^/PR^+^ and ER^+^/PR^+^, *P* \< 0.05, calculated by ANCOVA (adjusted WBC counts of controls). ^†^Difference between ER^+^/PR^−^ or ER^−^/PR^+^ vs. ER^−^/PR^−^ and ER^+^/PR^+^, *P* \< 0.05, calculated by ANCOVA (adjusted WBC counts of controls) (**b**).Table 3Characteristics of postmenopausal patients with breast cancer and age-matched controls according to obesity and ER/PR status.Non-obeseControls^a^\
(N = 422)ER^−^/PR^−^\
(N = 422)*p* value^b^Controls^a^\
(N = 11)ER^+^/PR^−^ or\
ER^−^/PR^+^\
(N = 411)*P* value^b^Controls^a^\
(N = 522)ER^+^/PR^+^\
(N = 522)*p* value^b^Age (years)57.2 (6.7)57.2 (6.7)0.99958.5 (7.3)58.5 (7.3)0.99957.7 (8.0)57.7 (8.0)0.999Body mass index (kg/m²)22.2 (1.9)22.2 (1.6)0.84622.3 (1.8)22.3 (1.7)0.62322.3 (1.7)22.4 (1.7)0.282Systolic blood pressure (mmHg)120.7 (18.7)126.1 (14.7)\<0.001124.0 (19.0)126.9 (15.2)0.013121.6 (17.6)128.2 (15.0)\<0.001Diastolic blood pressure (mmHg)75.7 (9.9)78.4 (9.4)\<0.00176.4 (10.2)77.0 (9.4)0.32475.1 (10.0)79.2 (9.7)\<0.001Fasting plasma glucose (mg/dL)98.4 (22.1)103.5 (21.7)0.01995.2 (12.3)103.5 (23.6)\<0.00195.2 (19.6)103.3 (24.4)\<0.001Total cholesterol (mg/dL)202.2 (35.7)195.2 (37.4)0.047200.8 (31.7)197.8 (31.8)0.442200.8 (34.3)196.6 (37.3)0.2211Triglyceride (mg/dL)122.9 (76.4)119.2 (64.6)0.510121.0 (77.1)116.3 (66.5)0.396118.6 (74.5)122.2 (73.3)0.5169HDL-cholesterol (mg/dL)55.1 (13.6)54.7 (12.6)0.65156.4 (13.6)54.5 (12.9)0.07456.0 (12.8)55.1 (11.9)0.312White blood cells (×10^3^ cell/μL)5.5 (1.5)5.6 (1.4)0.5265.5 (1.7)5.6 (1.6)0.8225.5 (1.4)5.9 (1.5)\<0.001Aspartate aminotransferase (IU)23.3 (12.0)21.6 (10.0)0.13122.2 (5.6)23.9 (23.1)0.42922.0 (6.8)23.4 (21.5)0.330Alanine aminotransferase (IU)21.8 (23.2)20.6 (13.1)0.52318.2 (6.8)20.7 (12.9)0.04618.3 (10.2)22.0 (21.5)0.019Age at menarche (years)15.7 (1.9)15.8 (1.8)0.51215.6 (2.0)15.7 (2.0)0.90915.8 (2.0)15.6 (2.0)0.195Age at menopause (years)49.0 (4.6)49.4 (5.1)0.14849.3 (4.5)50.0 (4.9)0.08848.4 (5.0)48.5 (6.2)0.608Breastfeeding (%)82.673.80.00287.069.9\<0.000186.170.1\<0.001Hypertension medication (%)22.028.00.03025.327.50.46921.830.3\<0.001Diabetes medication (%)6.210.00.0295.610.70.0097.310.60.058**ObeseControls** ^**a**^\
**(N = 228)ER** ^**−**^ **/PR** ^**−**^\
**(N = 228)*p*** **value** ^**b**^**Controls** ^**a**^\
**(N = 193)ER** ^**+**^ **/PR** ^**−**^ **or**\
**ER** ^**−**^ **/PR** ^**+**^\
**(N = 193)*P*** **value** ^**b**^**Controls** ^**a**^\
**(N = 346)ER** ^**+**^ **/PR** ^**+**^\
**(N = 346)*p*** **value** ^**b**^Age (years)59.5 (7.6)59.5 (7.6)0.99959.5 (7.4)59.5 (7.4)0.99960.4 (8.2)60.4 (8.2)0.999Body mass index (kg/m²)27.6 (2.3)27.4 (2.1)0.50027.6 (2.7)27.3 (2.1)0.17427.5 (2.7)27.7 (2.5)0.237Systolic blood pressure (mmHg)127.8 (16.5)129.0 (14.2)0.374127.3 (15.8)130.3 (14.4)0.045127.8 (17.2)131.8 (14.8)\<0.001Diastolic blood pressure (mmHg)78.3 (9.5)80.2 (8.7)0.04178.7 (9.2)80.0 (9.8)0.17678.2 (10.0)80.5 (10.0)0.002Fasting plasma glucose (mg/dL)103.4 (25.1)109.0 (27.4)0.114104.2 (24.6)108.1 (30.6)0.463101.5 (26.2)109.2 (26.7)0.014Total cholesterol (mg/dL)203.9 (40.5)196.2 (34.0)0.146215.5 (37.7)196.7 (35.3)0.002209.4 (39.3)200.2 (35.3)0.041Triglyceride (mg/dL)160.2 (87.0)143.0 (62.6)0.044161.8 (88.4)129.9 (60.2)\<0.001149.0 (79.8)152.6 (85.3)0.641HDL-cholesterol (mg/dL)51.2 (12.2)49.8 (10.6)0.29451.6 (12.0)51.5 (11.2)0.95650.4 (12.0)49.2 (9.6)0.247White blood cells (×10^3^ cell/μL)5.9 (1.5)5.9 (1.6)0.8675.9 (1.5)5.9 (1.5)0.9536.0 (1.6)6.3 (1.6)0.014Aspartate aminotransferase (IU)25.3 (15.7)23.3 (9.3)0.23923.9 (8.2)21.0 (7.0)0.02623.5 (9.2)23.5 (10.8)0.974Alanine aminotransferase (IU)23.7 (15.8)24.3 (14.3)0.74025.0 (13.7)21.4 (11.6)0.06424.1 (22.4)25.8 (15.3)0.399Age at menarche (years)16.1 (2.1)16.0 (1.9)0.70216.1 (2.3)15.7 (2.0)0.05615.8 (2.0)15.7 (1.8)0.478Age at menopause (years)49.1 (4.8)50.3 (5.0)0.00649.7 (4.4)50.2 (4.4)0.28149.1 (5.3)49.3 (5.5)0.686Breastfeeding (%)90.883.70.02091.780.70.00288.177.3\<0.001Hypertension medication (%)46.557.00.01642.545.60.52744.855.20.0058Diabetes medication (%)12.716.20.27616.118.10.58610.119.10.001Data are expressed as the mean (standard deviation) for continuous variables or the percentage for categorical variables. Non-obese group and obese were defined as body mass index\<25 kg/m² and ≥25 kg/m², respectively. ^a^Controls are propensity score-matched data. ^b^*p* values calculated using paired t-test or McNemar's test.

Figure [2b](#Fig2){ref-type="fig"} shows the differences in WBC counts between patients and matched controls by ER/PR status, menopause status, and obesity status. ANCOVA showed that the difference in WBC counts between patients and matched controls was significantly greater for premenopausal non-obese women with ER^+^/PR^+^ breast cancer than for those with ER^−^/PR^−^ breast cancer or ER^+^/PR^−^ or ER^−^/PR^+^ breast cancer (*p* = 0.020 and *p* = 0.038, respectively). Among postmenopausal women, the difference in WBC counts between patients and controls was greater for patients with ER^+^/PR^+^ breast cancer than for those with ER^−^/PR^−^ breast cancer or ER^+^/PR^−^ or ER^−^/PR^+^ breast cancer, regardless of whether the women were obese (*p* = 0.002 and *p* \< 0.001, respectively) or non-obese (*p* = 0.002 and *p* = 0.009, respectively).

Finally, we assessed the association between WBC count and breast cancer burden according to ER/PR status, BMI, and menopausal status. For the analysis, we used multinomial logistic regression analysis after adjustment for age, systolic blood pressure, fasting plasma glucose, total cholesterol, triglyceride, HDL cholesterol, alanine aminotransferase, the use of hypertension and diabetes medications, history of breastfeeding, menarchial age, and menopausal age (Table [4](#Tab4){ref-type="table"}, Fig. [3](#Fig3){ref-type="fig"}). Premenopausal non-obese patients with ER^+^/PR^+^ breast cancer had higher WBC counts than their age-matched controls \[odds ratio (95% CI) = 1.293 (1.139--1.363), *p* \< 0.001\]. Likewise, postmenopausal non-obese patients with ER^+^/PR^+^ breast cancer had higher WBC counts compared to their age-matched controls \[odds ratio (95% CI) = 1.049 (1.019--1.295), *p* = 0.023\]. Furthermore, premenopausal non-obese patients with ER^+^/PR^+^ breast cancer had higher WBC counts than premenopausal non-obese patients with ER^−^/PR^−^ breast cancer \[odds ratio (95% CI) = 1.203 (1.019--1.420), *p* = 0.029\]. Similarly, postmenopausal obese patients with ER^+^/PR^+^ breast cancer had higher WBC counts than postmenopausal obese patients with ER^−^/PR^−^ breast cancer \[odds ratio (95% CI) = 1.342 (1.023--1.760), *p* = 0.034\]. Menopause\*WBC, BMI\*WBC, and menopause\*BMI\*WBC were all shown to have significant interactions by multinomial logistic regression models for outcome (interaction *p* value = 0.126, 0.002, and 0.184, respectively).Table 4Multinomial logistic regression analysis showing the strength of correlation between WBC count and breast cancer status.Premenopause, BMI \< 25 kg/m²Premenopause, BMI ≥ 25 kg/m²OR (95% CI)*p* value^a^OR (95% CI)*p* value^a^Cases (ER^−^/PR^−^) vs. Controls1.075 (0.921--1.255)0.3581.170 (0.924--1.482)0.193Cases (ER^−^/PR^+^ or ER^+^/PR^−^) vs. Controls1.279 (1.061--1.541)0.0091.242 (0.817--1.890)0.310Cases (ER^+^/PR^+^) vs. Controls1.293 (1.185--1.411)\<0.0011.082 (0.915--1.279)0.356Cases (ER^−^/PR^+^ or ER^+^/PR^−^) vs. Cases (ER^−^/PR^−^)1.190 (0.941--1.504)0.1461.062 (0.663--1.700)0.802Cases (ER^+^/PR^+^) vs. Cases (ER^−^/PR^−^)1.203 (1.019--1.42)0.0280.925 (0.704--1.214)0.573Cases (ER^−^/PR^+^ or ER^+^/PR^−^) vs. Cases (ER^−^/PR^−^)1.011 (0.834--1.226)0.9100.871 (0.562--1.349)0.535**Postmenopause, BMI \< 25 kg/m²Postmenopause, BMI ≥ 25 kg/m²OR (95% CI)*p*** **value** ^**b**^**OR (95% CI)*p*** **value** ^**b**^Cases (ER^−^/PR^−^) vs. Controls0.966 (0.830--1.124)0.6530.820 (0.652--1.032)0.091Cases (ER^−^/PR^+^ or ER^+^/PR^−^) vs. Controls1.010 (0.849--1.201)0.9121.020 (0.821--1.269)0.855Cases (ER^+^/PR^+^) vs. Controls1.149 (1.019--1.295)0.0231.101 (0.936--1.294)0.245Cases (ER^−^/PR^+^ or ER^+^/PR^−^) vs. Cases (ER^−^/PR^−^)1.045 (0.838--1.304)0.6941.244 (0.914--1.693)0.165Cases (ER^+^/PR^+^) vs. Cases (ER^−^/PR^−^)1.189 (0.989--1.430)0.0641.342 (1.023--1.760)0.033Cases (ER^−^/PR^+^ or ER^+^/PR^−^) vs. Cases (ER^−^/PR^−^)1.138 (0.930--1.392)0.2101.079 (0.830--1.403)0.571^a^Premenopausal model: Adjusted for age, systolic blood pressure, fasting plasma glucose, total cholesterol, triglyceride, HDL-cholesterol, ALT, age at menarche, breastfeeding, hypertension medication, and diabetes medication.^b^Postmenopausal model: Adjusted for age, systolic blood pressure, fasting plasma glucose, total cholesterol, triglyceride, HDL-cholesterol, ALT, age at menopause, breastfeeding, hypertension medication, and diabetes medication.Figure 3Forest plot. Models of premenopausal women were adjusted for age, systolic blood pressure, fasting plasma glucose, total cholesterol, triglyceride, HDL cholesterol, alanine aminotransferase, age at menarche, breastfeeding, hypertension medication, and diabetes medication. Models of postmenopausal women were adjusted for age, systolic blood pressure, fasting plasma glucose, total cholesterol, triglyceride, HDL cholesterol, alanine aminotransferase, age at menopause, breastfeeding, hypertension medication, and diabetes medication. ^\*^Difference between control and ER^−^/PR^−^, ER^+^/PR^−^ or ER^−^/PR^+^, or ER^+^/PR^+^; *P* \< 0.05, calculated by multinomial logistic regression analysis. ^†^Difference between ER^−^/PR^−^ and ER^+^/PR^−^ or ER^−^/PR^+^, or ER^+^/PR^+^; *P* \< 0.05, calculated by multinomial logistic regression.

Discussion {#Sec7}
==========

In this case-control study, we found that WBC count was associated differently with breast cancer burden depending on menopausal status, BMI, and ER/PR status. Premenopausal non-obese women with ER^+^/PR^+^ breast cancer had elevated WBC counts compared with both controls and premenopausal non-obese women with ER^−^/PR^−^ breast cancer. Those trends were weaker in premenopausal obese women. Postmenopausal non-obese women with ER^+^/PR^+^ breast cancer had elevated WBC counts compared with controls, while postmenopausal obese women with ER^+^/PR^+^ breast cancer had elevated WBC counts compared with postmenopausal obese women with ER^−^/PR^−^ breast cancer.

Emerging evidence suggests that chronic low-grade inflammation plays an important role in cancer development. Both menopause and obesity can also play a crucial role in the development of breast cancer^[@CR30]^, but their interaction may differ according to menopausal status^[@CR22],[@CR31],[@CR32]^. Positive associations between obesity and breast cancer risk have been consistently observed in postmenopausal women^[@CR33]--[@CR36]^. However, there is substantial evidence that there is an inverse association between obesity and breast cancer risk in premenopausal women^[@CR37]--[@CR39]^. Our results showed that WBC count was not associated with breast cancer burden in premenopausal obese women.

WBCs, including neutrophils, monocytes, and eosinophils, produce reactive oxygen species (ROS) and nitric oxide species (NOS), which are chemically reactive molecules^[@CR40]^. Unless ROS and NOS are properly neutralized by the antioxidant defense system, they can cause damage to cellular proteins, lipids, and DNA that may lead to the accumulation of genetic instability, affecting single nucleotide polymorphisms (SNPs) or upregulating the PI3K-Akt pathway for carcinogenesis^[@CR41]^. Large-sample studies that attempted to evaluate the association between WBC counts and breast cancer risk without stratification by menopausal status and obesity have produced inconsistent results^[@CR24],[@CR25]^. A prospective study demonstrated that leukocyte counts may be a predictor of breast cancer, but the study included only postmenopausal women^[@CR20]^. Akinbami *et al*.^[@CR42]^ reported that WBC counts were higher in patients with breast cancer than in controls, but their study did not include information about menopausal status. Okuturlar *et al*. showed that neutrophil levels were associated with the risk of breast cancer, including Stage IV breast cancer^[@CR43]^. None of the previous studies included ER/PR status in their analysis. A recent meta-analysis assessed the association between the neutrophil-to-lymphocyte ratio as a biomarker using WBC subtypes and breast cancer prognosis^[@CR44]^. In that study, which was performed in patients with breast cancer without control, patients with a higher neutrophil-to-lymphocyte ratio had a higher relapse and a shorter overall survival. Subgroup analysis showed that studies performed in Eastern countries had perfectly homogeneous results, whereas Western countries did not. A distinguishing feature of our study is that it attempts to elucidate a role of the interaction between WBC count and ER/PR status in the context of menopause and BMI.

The prevalence of obesity among Korean women has gradually decreased since 2001^[@CR45]^, but the incidence of breast cancer has increased over the last decade^[@CR4]^. The age-frequency distribution of breast cancer among Korean women is unimodal, with peak incidence at 45--49 years of age^[@CR5]^. Dense breast on mammography, a potent risk factor for breast cancer, is more prevalent among Korean women, especially before menopause, than among women from Western countries^[@CR46]^. Those distinctive epidemiological features warrant more investigation of the interplay between well-known risk factors such as obesity and menopause and the emerging role of inflammation in cancer development.

While metabolic syndrome and insulin resistance, as inflammatory conditions, have been noticed to be associated with breast cancer development and subsequent progression^[@CR7]--[@CR9]^, there are controversies, regarding discrepancies according to menopause^[@CR21]--[@CR23]^, as well as some limitations in Korean women. One Korean cohort study in which 23,830 Korean women 50--64 years of age were examined reported that metabolic syndrome was related to the risk of breast cancer after adjustment for age and BMI^[@CR47]^. That study did not account for menopausal status, although most of the participants were likely postmenopausal, nor did it consider different breast cancer subtypes. A recent epidemiological study of postmenopausal Korean women showed that insulin resistance was independently associated only with luminal B subtype breast cancer^[@CR10]^, which is included in the ER^+^/PR^+^ phenotype^[@CR48]^.

ER and PR are found in about two-thirds of breast cancers, representing favorable therapeutic and prognostic factors. In terms of breast cancer pathogenesis, the risk of breast cancer development associated with weight gain, a surrogate for increasing subclinical inflammation, has been shown to be higher for ER^+^/PR^+^ breast cancer than for ER^−^/PR^−^ breast cancer^[@CR27]^. Approximately 40% of ER^+^ breast cancers fail to respond to hormone therapy^[@CR49]^. ER and PR status can be a precipitating factor in breast cancer development through its interplay with inflammation, which may also influence endocrine resistance. Pro-inflammatory cytokines, such as tumor necrosis factor-α (TNF-α), increase the transcriptional activity of the NF-κB and JNK pathways and may subsequently induce tumorigenesis or resistance to hormone therapy^[@CR50]^. In a case-case analysis of epidemiological risk factors for breast cancer, women less than 50 years of age with ER^−^/PR^−^ tumors were more likely to be obese than those with ER^+^/PR^+^ tumors^[@CR51]^. Obesity *per se* has been mainly associated with postmenopausal ER^+^/PR^+^ breast cancer^[@CR27]^. Our study reported that menopausal status, BMI, and WBC showed a significant interaction by multinomial logistic regression models. Considering how previous studies have shown that obesity can be associated differently with breast cancer status, our findings suggest that among non-obese women, WBC may be related to breast cancer burden. Among Korean women, breast cancer has peak incidence in the perimenopausal period, with the number of obese women being lower than that of non-obese women^[@CR10],[@CR52]^.

Our study has a few limitations. First, because our study was a case-control study, the exact cause-effect relationship between WBC count and ER/PR status according to obesity status and menopausal status remains unclear. Although it is plausible that WBC may reflect underlying inflammation and, in turn, affect breast cancer risk, higher WBC counts may result from the stress that comes after receiving a cancer diagnosis. Also, WBC counts in controls and cases were measured separately in different laboratories, with very high concordance of general blood cell counts among various automated hematology analyzers^[@CR53],[@CR54]^, which may have led to differential misclassification of laboratory errors. Prospective longitudinal studies are needed to verify the effects of those interactions on the development of breast cancer, especially in Asian women. Second, some inflammatory markers such as C-reactive protein, interleukin-6, serum amyloid-A, and prostaglandin E2 were not measured at the beginning of the study. Those markers can be indicators of chronic low-grade inflammation but have not been taken into consideration when relating breast cancer to the presence of obesity. Third, cases were selected from hospital registry between 2005 and 2012, but controls were selected between 2010 and 2012 from KNHANES, albeit for proper stratification in cases and for excluding duplication of participants and minimizing missing data in controls.

In conclusion, compared with those in controls, WBC counts were significantly elevated in non-obese patients with ER^+^/PR^+^ breast cancer, irrespective of menopause. Further larger-scale prospective cohort studies are warranted to determine these associations in the future.
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